Market Exclusive

Analyst Upgrades – Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Upgraded By Leerink Swann from Market Perform to Outperform

Analyst Ratings For Agios Pharmaceuticals (NASDAQ:AGIO)

Today, Agios Pharmaceuticals (NASDAQ:AGIO) stock received an upgrade by Leerink Swann from Market Perform to Outperform.

There are 3 hold ratings, 8 buy ratings on the stock.

The current consensus rating on Agios Pharmaceuticals (NASDAQ:AGIO) is Buy (Score: 2.73) with a consensus target price of $62.88 per share, a potential 7.20% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) has insider ownership of 10.55% and institutional ownership of 84.24%.

Recent Trading Activity for Agios Pharmaceuticals (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals closed the previous trading session at 58.65 0.00 0.00% with 2,149,385 shares trading hands.

Exit mobile version